The potential for digital initiatives for opioid harm reduction is boundless. Synthesized evidence on current interventions and their efficacy are emerging. This scoping review is an effort to aggregate Canadian and Australian digital health initiatives used to prevent opioid-related deaths and minimize harm, prior to and particularly during the pandemic of SARs-COVID-19, when the crisis...

The Committee’s investigation has uncovered significant, years-long conflicts of interest at McKinsey, resulting from its work for the federal government at the same time it was advising opioid manufacturers, including providing advice on how to influence the regulatory decisions of the U.S. Food and Drug Administration (FDA), another McKinsey client.

This report investigates the impact of darknet market closures (voluntary or exit scams) and law enforcement market seizures on the availability of fentanyl and other opioids.

In recent decades the range and patterns of opioids used for extra-medical purposes have changed. The use of pharmaceutical opioids exceeds the use of heroin. The objective of this report was to estimate the social costs arising from extra-medical opioid use in Australia for the financial year 2015/16.

This research investigates fentanyl use among police detainees participating in the Drug Use Monitoring in Australia program.